225Ac-PSMA放射配体治疗转移性去势抵抗性前列腺癌疗效的荟萃分析
该荟萃分析纳入9项研究共263例转移性去势抵抗性前列腺癌患者,评估225Ac-PSMA放射配体治疗的疗效与安全性。汇总结果显示60.99%患者PSA下降超过50%,83.57%患者出现任何PSA下降,中位无进展生存期9.15个月、总生存期11.77个月。常见不良事件为口干(62.81%)和严重血液毒性(贫血14.39%、白细胞减少4.12%、血小板减少7.18%)。
要点
- 225Ac-PSMA放射配体治疗后约61%患者PSA下降超过50%,84%患者出现任何PSA下降。
- 口干发生率为62.81%,严重贫血、白细胞减少、血小板减少分别为14.39%、4.12%、7.18%。
- 估计平均无进展生存期9.15个月,平均总生存期11.77个月。
核心结论
- 225Ac-PSMA放射配体治疗在转移性去势抵抗性前列腺癌中约61%患者PSA下降超过50%,84%患者出现任何PSA下降。
- 常见不良事件为口干(63%)和严重血液毒性(4%-14%)。
研究设计与样本
- 系统检索关键词为「mCRPC」「225Ac-PSMA」和「alpha therapy」的文献进行荟萃分析。
- 共纳入9项研究、263例转移性去势抵抗性前列腺癌患者。
主要发现
- PSA下降超过50%的汇总比例为60.99%(95%CI,54.92%-66.83%),任何PSA下降的汇总比例为83.57%(95%CI,78.62%-87.77%)。
- 估计平均无进展生存期为9.15个月(95%CI,6.69-11.03个月),平均总生存期为11.77个月(95%CI,9.51-13.49个月)。
- 口干汇总比例为62.81%(95%CI,39.34%-83.46%),贫血为14.39%(95%CI,7.76%-22.63%),白细胞减少为4.12%(95%CI,0.97%-9.31%),血小板减少为7.18%(95%CI,2.70%-13.57%)。
临床怎么用
- 对于转移性去势抵抗性前列腺癌患者,225Ac-PSMA放射配体治疗可作为PSMA靶向α治疗的选项之一。
- 治疗期间需关注口干和严重血液毒性(贫血、白细胞减少、血小板减少)的发生与监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA), overexpressed in prostate cancer, has become a popular target for radionuclide-based theranostic applications in the advanced stages of prostate cancer. We conducted a meta-analysis of the therapeutic effects of PSMA-targeting α-therapy (225Ac-PSMA radioligand therapy [RLT]) in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: A systematic search was performed using the keywords "mCRPC," "225Ac-PSMA," and "alpha therapy." Therapeutic responses were analyzed as the pooled proportions of patients with more than a 50% prostate-specific antigen (PSA) decline and any PSA decline. Survival outcomes were analyzed by estimating summary survival curves for progression-free survival and overall survival. Adverse events were analyzed as the pooled proportions of patients with xerostomia and severe hematotoxicity (anemia, leukocytopenia, and thrombocytopenia). Results: Nine studies with 263 patients were included in our meta-analysis. The pooled proportions of patients with more than a 50% PSA decline and any PSA decline were 60.99% (95% CI, 54.92%-66.83%) and 83.57% (95% CI, 78.62%-87.77%), respectively. The estimated mean progression-free survival and mean overall survival were 9.15 mo (95% CI, 6.69-11.03 mo) and 11.77 mo (95% CI, 9.51-13.49 mo), respectively. The pooled proportions of patients with adverse events were 62.81% (95% CI, 39.34%-83.46%) for xerostomia, 14.39% (95% CI, 7.76%-22.63%) for anemia, 4.12% (95% CI, 0.97%-9.31%) for leukocytopenia, and 7.18% (95% CI, 2.70%-13.57%) for thrombocytopenia. Conclusion: In our study, around 61% of patients had more than a 50% PSA decline and 84% of patients had any PSA decline after 225Ac-PSMA RLT. The common adverse events in 225Ac-PSMA RLT were xerostomia in 63% of patients and severe hematotoxicity in 4%-14% of patients.
引用
- Lee DY, Kim YI. Effects of 225Ac-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis. J Nucl Med. 2021. PMID: 34503960. doi:10.2967/jnumed.121.262017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。